共查询到20条相似文献,搜索用时 15 毫秒
1.
《Metallurgist》2013,57(7-8):659-661
2.
吕伟其 《Canadian Metallurgical Quarterly》2011,11(1)
根据危险化学品易燃、易爆、有毒的特点,提出安全储存和管理的管理思路,同时探讨了装卸入库的安全注意管理点. 相似文献
3.
4.
5.
M Yamamoto N Yokote M Morita T Nakano K Ishikawa T Kaminuma 《Canadian Metallurgical Quarterly》1997,(115):161-165
ge of the Japanese version of the International Chemical Safety Cards (ICSC). We prepared the Japanese text files of ICSC, converted them into HTML files and also prepared the dictionary database for the retrieval system, using programs which we developed. These programs shortened the time of work remarkably. 2D- and 3D-structures of chemicals were also incorporated in each ICSC page. Approximately 900 ICSCs in Japanese are provided at the moment on the homepage. 相似文献
6.
推行"一法三卡",对促进安全生产工作,维护职工安全健康合法权益起到了积极作用.要求领导重视,重点明确,组织落实. 相似文献
7.
Article comments on the Journal of Counseling Psychology's practice of inserting abstracts of articles printed on 3×5 cards. The Editor asked readers for their opinion about this proposed service and the comment author asserts that there is no doubt that the general establishment of this service in all professional journals would solve many troublesome problems of bibliographic documentation in psychology--but only if the majority of journals do it. The comment author then goes on the state that it would be also most desirable, though not necessary for the introduction of abstract cards, to develop some classification of the subject matter, and to print abstract cards with symbols of proper divisions. (PsycINFO Database Record (c) 2010 APA, all rights reserved) 相似文献
8.
9.
提出一种基于智能卡的可信双向认证方案,使用散列函数认证身份,采用远程证明方法验证平台可信性.该方案支持安全会话密钥协商,支持用户身份匿名及口令自由更换,服务器平台证书可更新.分析表明,该方案可以抵抗针对智能卡口令认证方案的常见攻击,安全高效,满足安全设计目标. 相似文献
10.
11.
12.
C Hawkey A Kahan K Steinbrück C Alegre E Baumelou B Bégaud J Dequeker H Isom?ki G Littlejohn J Mau S Papazoglou 《Canadian Metallurgical Quarterly》1998,37(9):937-945
Although widely used, non-steroidal anti-inflammatory drugs (NSAIDs) are associated with a high incidence of gastrointestinal (GI) side-effects. Inhibition of the cyclooxygenase (COX) enzyme is the basis for both the efficacy and toxicity of NSAIDs. The discovery of two COX isoforms, constitutive COX-1 and inducible COX-2, has led to the hypothesis that selective inhibition of COX-2 will minimize the potential for GI toxicity without compromising efficacy. The Meloxicam Large-scale International Study Safety Assessment (MELISSA) trial reported here was therefore set up to investigate the tolerability of meloxicam, a preferential inhibitor of COX-2, compared to diclofenac. MELISSA was a large-scale, double-blind, randomized, international, prospective trial, conducted over 28 days in patients with symptomatic osteoarthritis. Patients received either meloxicam 7.5 mg or diclofenac 100 mg slow release, the recommended doses for the treatment of osteoarthritis. Evaluation of the profile of adverse events was the main aim of the trial, together with assessment of efficacy. A total of 9323 patients received treatment (4635 and 4688 in the meloxicam and diclofenac groups, respectively). Significantly fewer adverse events were reported by patients receiving meloxicam. This was attributable to fewer GI adverse events (13%) compared to diclofenac (19%; P < 0.001). Of the most common GI adverse events, there was significantly less dyspepsia (P < 0.001), nausea and vomiting (P < 0.05), abdominal pain (P < 0.001) and diarrhoea (P < 0.001) with meloxicam compared to diclofenac. Five patients on meloxicam experienced a perforation, ulcer or bleed vs seven on diclofenac (not significant). No endoscopically verified ulcer complication was detected in the meloxicam group compared to four with diclofenac. There were five patient days of hospitalization in patients on meloxicam compared to 121 with diclofenac. Adverse events caused withdrawal from the study in 254 patients receiving meloxicam (5.48%) compared to 373 (7.96%) on diclofenac (P < 0.001). These differences were attributable to differences in reported GI adverse events (3.02% on meloxicam vs 6.14% on diclofenac; P < 0.001). Differences in efficacy, as assessed by visual analogue scales, consistently favoured diclofenac. In all instances, 95% confidence intervals did not cross zero, suggesting a statistically significant effect. However, differences were small (4.5-9.01% difference) and did not reach pre-determined levels of clinical significance. Nevertheless, significantly more patients discontinued meloxicam because of lack of efficacy (80 out of 4635 vs 49 out of 4688; P < 0.01). The MELISSA trial confirms earlier studies suggesting that meloxicam has a significantly improved GI tolerability profile in comparison with other NSAIDs, including diclofenac. These results may in part reflect the preferential COX-2 selectivity of meloxicam, although the dose and other aspects of tolerability may be important. These results may provide support for the hypothesis that selective inhibition of COX-2 relative to COX-1 might be an effective approach towards improved NSAID therapy. 相似文献
13.
程玉河 《Canadian Metallurgical Quarterly》2011,11(3)
分析了危化品企业在实施安全生产标准化过程中常见的主要问题或难点,并针对这些问题或难点提出了对策措施及建议. 相似文献
14.
E Ryu 《Canadian Metallurgical Quarterly》1976,15(7):517-518
15.
EK Silbergeld 《Canadian Metallurgical Quarterly》1995,1(4):336-348
Lead poisoning is among the most prevalent and serious preventable diseases of occupational and environmental origin. Many sources contribute to human exposures, and the residues from past uses continue to present risks due to contamination of dusts, soils, and drinking water. In many aspects, lead poisoning is a local-scale problem, and factors in specific environments and workplaces, as well as characteristics of specific populations, determine the nature and extent of disease. However, lead is also a global pollutant: emissions from stationary and mobile sources are transported across boundaries and even oceans; lead-containing products are traded extensively; and lead-containing wastes such as batteries also move internationally. For these reasons, national regulations are insufficient to prevent this disease. This paper discusses evidence for undertaking international efforts to control lead exposures. 相似文献
17.
19.
20.
We have examined the reversal of the regulatory effect of growth factors on calpain/calpastatin activity in transfected Schwann cells (tSc) after their subsequent withdrawal. Removal of nerve growth factor (NGF) or cyclic adenosine monophosphate (cAMP) from tSc resulted in a smaller loss of mu calpain (37%) and mcalpain (36.5 %) activity compared to treated cells from which the growth factors were not withdrawn. The mu calpain activity increased approximately 12% following withdrawal of acidic fibroblast growth factor (aFGF) and basic fibroblast growth factor (bFGF) at 24 hr, while the increased mcalpain activity was more than 30-40% compared with that of cells that were continuously treated. The activity of both isoforms returned to their normal levels (untreated) at 48-72 hr following withdrawal of various growth factors, including NGF, cAMP, aFGF, bFGF, platelet-derived growth factor aa (PDGFaa), and PDGFbb. The inhibitory activity of calpastatin was greater than control following withdrawal of NGF, cAMP, PDGFaa, or PDGFbb at 24 hr and this inhibitory activity was less with treatment by aFGF and bFGF. The control activity was restored at 48 hr following withdrawal of these factors. The intensity of the cytoplasmic calpain immunoreactivity was significantly decreased in the nuclear and non-nuclear regions of the cytoplasm, respectively, following withdrawal of cAMP at 144 hr. Removal of bFGF from the medium resulted in an increase of cytoplasmic calpain immunoreactivity in the nuclear regions and cytoplasm, while there was dramatic loss of myelin calpain immunoreactivity from both the nuclear region and cytoplasm. The changes in calpain activity and immunoreactivity in tSc following withdrawal of growth factors suggest that release of calpain from membrane to cytosol may be regulated by these factors. 相似文献